SOUTH SAN FRANCISCO, Calif., July 3 /PRNewswire-FirstCall/ -- Sunesis
Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that Daniel Swisher,
Sunesis' Chief Executive Officer and President, will provide a corporate
overview at the upcoming Collins Stewart Fourth Annual Growth Conference at
2:30 p.m. Eastern Time on July 8, 2008 in New York, NY.
Interested parties may access a webcast of the presentation by visiting
the Sunesis website at http://ir.sunesis.com. A replay of the webcast will be
archived on the "Calendar of Events" page in the Investors and Media section
of the Sunesis website for two weeks.
About Sunesis Pharmaceuticals
Sunesis is a clinical-stage biopharmaceutical company focused on the
development of new oncology therapeutics for the treatment of solid and
hematologic cancers. Sunesis has built a highly experienced cancer drug
development organization committed to advancing its lead product candidate,
voreloxin (formerly SNS-595), in multiple indications to improve the lives of
people with cancer. For additional information on Sunesis Pharmaceuticals,
please visit http://www.sunesis.com.
SUNESIS and the logo are trademarks of Sunesis Pharmaceuticals, Inc.
SOURCE Sunesis Pharmaceuticals, Inc.
